Exploring the capabilities of a versatile, novel, automated closed system for cell and gene therapy manufacturing

Cell & Gene Therapy Insights 2021; 7(2), 281–295


Published: 25 March 2021
Innovator Insight
Sarah Daoudi, Premkumar Jayaraman

As more cell and gene therapies move toward clinical trials, and into commercialization, new trends and challenges are emerging. Technologies and processes are rapidly evolving, and it can be challenging for manufacturers to select the best tools for their unique needs. Focusing on cell therapy manufacture in particular, there is a lack of specific equipment and products, and as such the resulting manufacturing workflows can be highly labor-intensive, often involving open processes and manual manipulations. Closed manufacturing systems, in combination with digital connectivity, can offer a solution to some of these challenges, as these systems enable repeatable, trackable, and GMP-compliant manufacturing processes. This article will discuss the benefits of moving towards modular, closed-system technologies designed for scalable and cost-effective manufacturing, with a focus on the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System – a revolutionary closed benchtop system which offers exceptional flexibility for cell washing, concentration, and separation by size.